<html>
<head>
<title>Untitled Document</title>

</head>

<body bgcolor="#FFFFFF" text="#000000">

<p align="center">&nbsp;</p>
<p align="center">&nbsp;</p>
<p align="center">&nbsp;</p>
<table width="79%" border="0" cellpadding="0" cellspacing="0">
  <tr>
    <td width="28%" valign="top">PFIZER LOGO</td>
    <td width="28%" valign="top"><p>Pfizer Inc<br>
235 East 42 Street<br>
New York, NY 10017</p></td>
  </tr>
  <tr>
    <td width="28%" valign="top">&nbsp;</td>
    <td width="28%" valign="top"><p>&nbsp;</p></td>
  </tr>
  <tr>
    <td valign="top">&nbsp;</td>
    <td valign="top"><p><strong>Matthew Lepore</strong><strong><br>
    <strong>Vice President and Corporate Secretary, <br>
    </strong></strong><strong>Chief Counsel &ndash; Corporate  Governance</strong></p></td>
  </tr>
</table>
<p><br>
  <br>
  February 28, 2013<br>
</p>
<p><strong><em>VIA EDGAR</em></strong></p>
<p>U.S. Securities and Exchange  Commission<br>
  100 F Street, N.E.<br>
  Washington, DC 20549<br>
</p>
<table border="0" cellspacing="0" cellpadding="0" width="100%">
  <tr>
    <td width="3%" valign="top"><p><strong>Re:</strong></p></td>
    <td width="72%" valign="top"><p><strong>Notice of disclosure filed in Annual Report on Form 10-K under  Section&nbsp;219 of </strong></p></td>
  </tr>
</table>
<table border="0" cellspacing="0" cellpadding="0" width="100%">
  <tr>
    <td width="3%"><p>&nbsp; </p></td>
    <td width="72%" valign="top"><p><strong>the Iran Threat Reduction and Syria Human Rights Act of 2012 and  Section&nbsp;13(r)&nbsp;of </strong></p></td>
  </tr>
</table>
<table border="0" cellspacing="0" cellpadding="0" width="100%">
  <tr>
    <td width="3%"><p>&nbsp; </p></td>
    <td width="72%" valign="top"><p><strong>the Securities and Exchange Act of 1934, as amended</strong></p></td>
  </tr>
</table>
<p>Ladies and Gentlemen:</p>
<p>Pursuant to  Section&nbsp;219 of the Iran Threat Reduction and Syria Human Rights Act of  2012 and Section&nbsp;13(r) of the Securities Exchange Act of 1934, as amended,  notice is hereby provided that Pfizer Inc. has made disclosure pursuant to such  provisions in its Annual Report on Form 10-K for the fiscal year ended  December&nbsp;31, 2012, which was filed with the U.S. Securities and Exchange  Commission on February&nbsp;28, 2013.</p>
<p>Respectfully submitted,</p>
<table border="0" cellspacing="0" cellpadding="0" width="79%">
  <tr>
    <td width="28%" valign="top"><p><u>/s/ Matthew Lepore</u></p></td>
  </tr>
  <tr>
    <td width="28%" valign="top"><p>Title: Vice President and Corporate Secretary,</p></td>
  </tr>
  <tr>
    <td valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Counsel - Corporate Governance</td>
  </tr>
</table>
<p align="left">&nbsp;</p>
</body>
</html>
